Mania News and Research

RSS

Articles explore clinical dilemma about children's behavioral problems

Clinicians often face the challenge of trying to make sense of conflicting reports from parents, teachers, and children about a child's behavioral problems. However, a better understanding of the source and nature of these disagreements may provide important information that could improve treatment and outcomes. A group of articles in the current issue of Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal published by Mary Ann Liebert, Inc., explores this challenging clinical dilemma.

2 Nov 2011

Forest Laboratories second quarter net sales increase 9.0% to $1,130.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that reported earnings per share equaled $0.91 in the second quarter of fiscal 2012. Reported earnings per share in the second quarter of fiscal 2011 were $1.00.

18 Oct 2011

Common DNA variations contribute to schizophrenia, bipolar disorder

A team of over 250 researchers from more than 20 countries have discovered that common genetic variations contribute to a person's risk of schizophrenia and bipolar disorder.

20 Sep 2011

ERWW PR forms Health Buzz Group

Euro RSCG Worldwide PR (ERWW PR) announces the formation of its Health Buzz Group, a global division created in response to growing client interest in big, splashy “wows” from small budgets in quick time frames using traditional and social media to generate momentum.

20 Sep 2011

Scientists discover common genetic variants associated with schizophrenia and bipolar disorder

Common genetic variants contribute to the risk of schizophrenia and bipolar disorder, an international research consortium has discovered.

19 Sep 2011

Landmark international study confirms common genetic contribution to mental illness

An international research consortium has confirmed that common genetic variants contribute to a person’s risk of schizophrenia and bipolar disorder. The largest study of its kind provides new molecular evidence that 11 regions have strong association with these diseases, including six regions not previously observed. The researchers also found that many of these DNA variations contribute to both diseases. The findings, reported by the Psychiatric Genome-Wide Association Study Consortium (PGC) and published online in two papers in the journal Nature Genetics, represent significant advances in the understanding the causes of these severe and often debilitating disorders.

18 Sep 2011

Risperidone recall by J&J

Ortho-McNeil-Janssen Pharmaceuticals Inc., a unit of Johnson & Johnson, recalled about 16,000 bottles of its Risperdal schizophrenia drug on reports of an uncharacteristic odor. The recall affects one lot that was shipped between Aug. 27, 2010, and Feb. 15, 2011.

19 Jun 2011

Homelessness and mental illness link explored in RMIT study

In a new study by the RMIT University, Victoria researchers looked at cases of 4,291 people using homelessness services in the city. Dr Guy Johnson and Professor Chris Chamberlain found almost half of them - 46 per cent - lost their homes after a family breakdown. This is contrary to the long held belief that most homeless people are mentally unstable.

7 Jun 2011

Psychotherapeutic treatment can cure cyclothymic disorder

In the current issue of Psychotherapy and Psychosomatics a group of Italian investigators headed by Giovanni Fava published a randomized controlled trial on psychotherapeutic treatment of cyclothymic disorder, a disturbance that is characterized by rapid alternation of mood swings.

9 May 2011

Catherine Zeta Jones treated for bipolar disorder

Catherine Zeta Jones – the 41-year-old Welsh actor checked into a day clinic in Connecticut for five days earlier this month for the treatment of bipolar disorder. “After dealing with the stress of the past year, Catherine made the decision to check in to a mental health facility for a brief stay to treat her Bipolar II Disorder,” said publicist Cece Yorke said in a statement adding, “She's feeling great and looking forward to starting work this week on her two upcoming films.”

13 Apr 2011

Prevalence of bipolar disorder

Bipolar disorder is a psychiatric disorder that swings between depression and mania. It strikes early and can cause lifelong disability. Reports show that it is chronically undertreated in many low-income countries.

7 Mar 2011

New study provides fascinating insight into genetic basis of bipolar disorder

A new study provides fascinating insight into the genetic basis of bipolar disorder, a highly heritable mood disorder characterized by recurrent episodes of mania and depression.

3 Mar 2011

Preliminary top-line results from cariprazine 8-week Phase II trial against major depressive disorder

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine as adjunctive therapy in major depressive disorder.

28 Feb 2011

Repligen third quarter total revenue increases 26% to $7,068,000

Repligen Corporation today reported results for the third quarter of fiscal year 2011, ended December 31, 2010. Total revenue for the quarter was $7,068,000 compared to total revenue of $5,617,000 for the third quarter of fiscal year 2010 ended December 31, 2009, an increase of $1,451,000 or 26%.

9 Feb 2011

NIMH awards Case Western Reserve $7.8M renewal grant to study manic symptoms in children

The Department of Psychiatry at Case Western Reserve University School of Medicine has received a $7.8 million renewal grant from the National Institute of Mental Health (NIMH) for the long-term study of manic symptoms in children.

21 Jan 2011

MGH Bipolar CHOICE trial to evaluate effectiveness of new medications compared to lithium

The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE, a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder.

21 Jan 2011

UH, Case Western University commence clinical trial for bipolar disorder

The Mood Disorders Program at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, along with the Bipolar Trials Network, is launching Bipolar CHOICE.

12 Jan 2011

Repligen 2011 second quarter total revenue increases 35% to $7,307,000

Repligen Corporation today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.

2 Nov 2010

Repligen Corporation completes patient enrollment in RG2417 Phase 2b clinical trial

Repligen Corporation reported today that it has completed enrollment of patients in its Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression.

30 Sep 2010

Teens who experience manic phase of bipolar disorder more likely to engage in high risk sexual behaviors

Although research has shown that teens with mental health disorders are more likely to engage in high risk sexual behaviors, like unprotected sex, a new study from the Bradley Hasbro Children's Research Center suggests there is an additional risk associated with certain psychiatric diagnoses.

29 Sep 2010